Search Blog
Categories
June 2018
M T W T F S S
« May   Jul »
 123
45678910
11121314151617
18192021222324
252627282930  

Tags

FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm

ACCESSWIRE

By Kaskela Law LLC

RADNOR, PA / ACCESSWIRE / June 30, 2018 / A shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ: ESPR) (“Esperion” or the “Company”) on behalf of investors who purchased the Company’s common stock between February 22, 2017 and May 1, 2018, inclusive (the “Class Period”).

FINAL DEADLINE ALERT: Investors who purchased Esperion’s common stock during the Class Period may, no later than July 6, 2018, seek to be appointed as a lead plaintiff of the investor class.

Esperion investors are encouraged to contact Kaskela Law LLC (David Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 – 1740 to discuss their important legal rights and options with respect to this action prior to July 6, 2018. Investors may also visit http://kaskelalaw.com/case/esperion-therapeutics-inc/ to submit their information to the firm online.

On May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion also disclosed that, although the trial met certain primary endpoints, there were 13 deaths in the treatment group as compared to only two in the control group. Following this news, shares of the Company’s stock declined $24.75 per share, or over 35%, to close on May 2, 2018 at $45.75.

The shareholder class action lawsuit alleges, among other things, that Esperion and certain of its senior executive officers made false and misleading statements and/or failed to disclose to investors that the Company’s cholesterol-lowering medication entailed serious undisclosed safety risks, including death. The complaint further alleges that, as a result of the foregoing, investors purchased Esperion’s stock at artificially inflated prices during the Class Period and suffered significant investment losses following the Company’s May 2, 2018 disclosure.

Esperion investors are encouraged to contact Kaskela Law LLC at (484) 258 – 1585 or (888) 715 – 1740, or via http://kaskelalaw.com/case/esperion-therapeutics-inc/, to discuss their legal rights and options prior to July 6, 2018. Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLC
David Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(484) 258 – 1585
(888) 715 – 1740
skaskela@kaskelalaw.com
www.kaskelalaw.com

SOURCE: Kaskela Law LLC

ReleaseID: 504191